- Conditions
- Coronary Artery Disease
- Interventions
- ComboMap XT Guidewire, 'SPY' NIRF During CABG
- Device · Procedure
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 781
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- PET MPI, SPECT MPI, Pharmacological stress agents
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
- Conditions
- Liver Cancer
- Interventions
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Winston-Salem, North Carolina
- Conditions
- Intracerebral Hemorrhage
- Interventions
- recombinant activated factor VII, placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 5 more
- Conditions
- Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis, Pulmonary Embolism Subacute Massive, Pulmonary Embolism Acute Massive
- Interventions
- Non-invasive hemodynamic measurements
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Coronary Syndrome, Chest Pain
- Interventions
- Not listed
- Lead sponsor
- Kavitha Chinnaiyan
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Carotid Stenosis
- Interventions
- [F-18]RDG-K5
- Drug
- Lead sponsor
- Siemens Molecular Imaging
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation, Contrast Media
- Interventions
- Intravenous administration of iodinated contrast medium for coronary CT angiography
- Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Coronary Artery Disease
- Interventions
- treatment with the Azurion system with Xres5, Azurion with Clairy IQ
- Device · Other
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 824 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Atlanta, Georgia • New York, New York
- Conditions
- Coronary Artery Disease, Atherosclerosis, Cardiovascular Inflammation
- Interventions
- CaRi-Heart® Analysis
- Device
- Lead sponsor
- Corazon Medical PC
- Other
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Bay City, Michigan • Berkley, Michigan • Caro, Michigan + 15 more
- Conditions
- Brain Lesions
- Interventions
- Contrast
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Diabetic Retinopathy
- Interventions
- triamcinolone acetonide (Kenalog)
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Ischemia
- Interventions
- Angiogram, Medtronic DCB (paclitaxel)/stent, Angiogram, Bard DCB (paclitaxel)/stent
- Device
- Lead sponsor
- Rabih A. Chaer
- Other
- Eligibility
- 40 Years to 95 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Embolism
- Interventions
- Not listed
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Interventions
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Diagnostic Test · Device · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Coronary Arteriosclerosis
- Interventions
- Rosuvastatin calcium
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Heart Disease
- Interventions
- noninvasive tests
- Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2040
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Coronary Artery Disease
- Interventions
- Isovue 370, 70 mL, Isovue 370, 80 mL, Isovue 370, 90 mL
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Prostate Carcinoma, Recurrent Prostate Carcinoma
- Interventions
- Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
- Drug · Behavioral · Procedure + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 30 Years to 79 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
- Conditions
- Atherosclerosis
- Interventions
- Magnetic resonance angiography
- Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland